The effect of Neurobion in the treatment of Thalassemia

The effectiveness of Neurobion in improving the general health of patients with thalassemia major referred to the hospital

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180602039941N1

Enrollment

Registered

2020-09-29

Start date

2018-12-22

Completion date

Unknown

Last updated

2020-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major Thalassemia.

Interventions

Intervention 1: Intervention group: Twenty Patients with Thalassemia major over 10 years of age who receive Neurobion. Intervention 2: Control group:Patients with Thalassemia major over the age of 10

Eligibility

Sex/Gender

All

Age

10 Years to No maximum

Inclusion criteria

Inclusion criteria: All patients with Thalassemia major over 10 years of age

Exclusion criteria

Exclusion criteria: Patients who do not wish to participate in this plan Patients with Hepatitis and Renal failure Patients with Thalassemia major under 10 years of age Patients with alloimmunization Patients who do not receive Zinc sulfate, Calcium and Folic acid

Design outcomes

Primary

Measure	Time frame
Score of physical symptoms, anxiety, sleep disorder and depression in questionnaire number two. Timepoint: Measurement of monthly hemoglobin after neurobion injection. Method of measurement: Blood test and questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFateme sahamipourdehqan

Arak University of Medical Sciences

info@arakmu.ac.ir+98 86 3313 6055

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026